Nasdaq

Where Will DexCom Be in 5 Years?

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...

Q4 Preliminary Figures and 2026 Guidance Make DexCom (DXCM) Look Attractive

DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the ...

Is DexCom (DXCM) Pricing Reflect Longer Term Returns And Glucose Monitoring Growth Story

If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...
MobiHealthNews

Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Is DexCom (DXCM) Pricing Justified After Recent Multi Year Share Price Weakness

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...
Business Wire

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...